Literature DB >> 24597695

Studying the association of microRNA-210 level with chronic hepatitis B progression.

G Song1, H Jia, H Xu, W Liu, H Zhu, S Li, J Shi, Z Li, J He, Z Chen.   

Abstract

We studied the relationship between hypoxia and microRNA-210 (miR-210) levels, the miR-210 levels in patients with hepatitis B and the roles of miR-210 in liver inflammation. We used the concanavalin A (Con A) murine hepatitis model and inflammation, hypoxia and miR-210 levels were examined. In these patients, we studied serum miR-210 levels and clinical indexes related to hepatitis in 90 patients with different stages of chronic hepatitis B and 30 controls. Two functional assays of miR-210 in vitro under hypoxic condition were conducted. The animal experiments indicated that the liver and serum miR-210 levels significantly increased with liver hypoxia and inflammation. In humans, serum miR-210 levels enhanced with hepatitis severity and were related to serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB) and prothrombin activity (PTA) levels. The miR-210 functional assays showed that miR-210 elevation might be related to the decreases in HepG2.2.15 cell dehydrogenase activity and HBV replication under hypoxic conditions. Because the liver inflammation causes liver hypoxia which also results in liver and serum miR-210 level elevation, the serum miR-210 level may serve as a molecular biomarker for the severity of hepatitis and increases in liver miR-210 that we see may be a response of hepatocytes to hypoxia during hepatitis progression.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  biomarker; chronic hepatitis B; hepatitis progression; hypoxia; inflammation; miR-210

Mesh:

Substances:

Year:  2013        PMID: 24597695     DOI: 10.1111/jvh.12138

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  11 in total

Review 1.  Hypoxic/Ischemic Inflammation, MicroRNAs and δ-Opioid Receptors: Hypoxia/Ischemia-Sensitive Versus-Insensitive Organs.

Authors:  Yimeng Chen; Yichen He; Shuchen Zhao; Xiaozhou He; Dong Xue; Ying Xia
Journal:  Front Aging Neurosci       Date:  2022-05-09       Impact factor: 5.702

Review 2.  Complex interactions between microRNAs and hepatitis B/C viruses.

Authors:  Hong-Xia Fan; Hua Tang
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

3.  Serum MicroRNA Transcriptomics and Acute Rejection or Recurrent Hepatitis C Virus in Human Liver Allograft Recipients: A Pilot Study.

Authors:  Thangamani Muthukumar; Kemal M Akat; Hua Yang; Joseph E Schwartz; Carol Li; Heejung Bang; Iddo Z Ben-Dov; John R Lee; David Ikle; Anthony J Demetris; Thomas Tuschl; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2022-04-01       Impact factor: 4.939

4.  Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients.

Authors:  Jin Li; Xiaonan Zhang; Liang Chen; Zhanqing Zhang; Jiming Zhang; Weixia Wang; Min Wu; Bisheng Shi; Xinxin Zhang; Maya Kozlowski; Yunwen Hu; Zhenghong Yuan
Journal:  Sci Rep       Date:  2017-11-15       Impact factor: 4.379

5.  Overexpression of miR-210 and its significance in ischemic tissue damage.

Authors:  G Zaccagnini; B Maimone; P Fuschi; D Maselli; G Spinetti; C Gaetano; F Martelli
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

Review 6.  Circulating microRNAs as Potential Biomarkers of Infectious Disease.

Authors:  Carolina N Correia; Nicolas C Nalpas; Kirsten E McLoughlin; John A Browne; Stephen V Gordon; David E MacHugh; Ronan G Shaughnessy
Journal:  Front Immunol       Date:  2017-02-16       Impact factor: 7.561

7.  Role of circRNAs in viral infection and their significance for diagnosis and treatment (Review).

Authors:  Yuyao Mo; Yuze Liu; Anni Lu; Hanyi Zhang; Lijun Tang
Journal:  Int J Mol Med       Date:  2021-03-31       Impact factor: 4.101

Review 8.  Circulating microRNAs as non-invasive biomarkers for hepatitis B virus liver fibrosis.

Authors:  Diana Gabriela Iacob; Adelina Rosca; Simona Maria Ruta
Journal:  World J Gastroenterol       Date:  2020-03-21       Impact factor: 5.742

Review 9.  Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms.

Authors:  Claudia Sirbe; Gelu Simu; Iulia Szabo; Alina Grama; Tudor Lucian Pop
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

10.  Cisplatin chemotherapy-induced miRNA-210 signaling inhibits hepatocellular carcinoma cell growth.

Authors:  Huan Yu; Guangyue Shi
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.